TNFRSF1B and melanoma: In this study nested within the E1694 GMK trial arm, we identify four markers: C-reactive protein (CRP), Tissue inhibitor of Metalloproteinases 1 (TIMP-1), Tumor Necrosis Factor alpha Receptor II (TNF-RII) and Transforming Growth Factor alpha (TGF-α) where the linear combination in the analysis of our model generates a risk score that has a significant prognostic value for high risk melanoma patients.